This study explored the efficacy and safety of combination pharmacological cardioversion of permanent atrial fibrillation in outpatients following prosthetic mitral valve replacement. The study group comprised 99 outpatients who were randomly divided into two groups. In group 1 (n = 50), only ventricular heart rate was controlled. In group 2 (n = 49), combination pharmacological cardioversion therapy with low-dose oral amiodarone (2 mg/kg), captopril (0.25 mg/kg) and simvastatin (0.3 mg/kg) was administered daily. During 12 months of serial pharmacological treatment, the cardioversion rate was 6% for group 1 and 39% for group 2; the likelihood of cardioversion differed significantly between the two groups. In group 2, one patient developed severe pruritus that necessitated withdrawal from the study and six patients ceased captopril treatment after contracting a persistent cough.
Introduction
Atrial fibrillation (AF) is one of the most common arrhythmias for patients with valvular heart disease; > 40% of patients referred for mitral valve surgery have continuous AF. 1 Although prosthetic mitral valve replacement (PMVR) has been shown to improve haemodynamics and to alleviate symptoms, permanent AF was still present in a majority of patients. 2 Patients who YJ Qian, XJ Xiao, HS Yuan et al. Combined drug cardioversion of atrial fibrillation remained in AF following mitral valve surgery had a lower survival at 3 and 5 years compared with those in sinus rhythm; however, this has not been observed in all studies. 3 The traditional approaches to AF treatment are either to restore a normal sinus rhythm (rhythm control) or to reduce the heart rate (ventricular rate control). The best method for controlling ventricular rate is by conversion to sinus rhythm. 4 Cardioversion is often performed electively to restore sinus rhythm in patients with permanent AF. Horstkotte 5 reported that sinus rhythm was restored in only 8% of AF patients after PMVR. Conversion to sinus rhythm is difficult, however, in post-PMVR patients using therapeutic measures such as catheter radiofrequency ablation, Wolf minimaze and electroversion. At present, pharmacological cardioversion is usually carried out during hospitalization so it is not known if permanent AF in post-PMVR patients can be successfully converted in an outpatient setting.
Pathological changes in the atrium that occur during the development of valve disease can predispose a patient to AF. Once AF has developed, these pathological changes may mean that conventional antiarrhythmic drugs prove ineffective at restoring sinus rhythm. 6 AF produces both atrial electrical and structural remodelling. 7 -9 Both of these contribute to the recurrence and maintenance of AF 10 -12 therefore, both should be considered 7 when attempting pharmacologically to convert post-PMVR permanent AF to sinus rhythm. The pharmacological prevention of atrial electrical remodelling has been troublesome, although blockers of the renin-angiotensin system and, perhaps, statins may reduce atrial structural remodelling by preventing atrial fibrosis. 13, 14 Amiodarone is a highly effective antiarrythmic, although it has many common side-effects, some of which are potentially fatal and most of which are dose related. 4, 15 Kochiadakis et al., 16 however, showed that a low dose of amiodarone (≤ 200 mg/day) could be used safely to convert AF to sinus rhythm. Considering the specific nature of the present study, planned in an outpatient clinic, a low dose of oral amiodarone was used to avoid serious sideeffects. Pharmacological cardioversion, therefore, that combined amiodarone with an antihypertensive angiotensin-converting enzyme (captopril) and a statin (simvastatin) was chosen for this study to address directly the electrical and structural remodelling of the atrial tissue in post-PMVR outpatients.
Patients and methods

PATIENTS
All patients provided informed consent for inclusion in the study and the protocol was approved by the ethics committee of West China Hospital. Patients who were >18 years of age who had permanent AF for at least 6 months after PMVR were included in the study. Two separate electrocardiographic confirmations of AF were required to confirm the diagnosis of permanent AF. Patients were excluded from the study on the basis of the following criteria: moderate or severe tricuspid regurgitation; New York Heart Association heart failure class IV; a history of sick sinus syndrome or a history of second or third degree atrioventricular block; significant thyroid, pulmonary or hepatic disease and/or contraindications to treatment with amiodarone; significant impairment of renal function; pregnancy or females shortly intending to become pregnant; or any other medical condition that, in the opinion of the investigators, could make the patient inappropriate for the study.
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Outpatients enrolled in accordance with the inclusion and exclusion criteria were randomized into one of two groups: group 1, in which ventricular heart rate was controlled; or group 2, in which combination pharmacological cardioversion therapy was used. Before randomization, all patients underwent a physical examination, 12-lead electrocardiography (ECG), echocardiography, and biochemical and haematological testing. These examinations were performed at baseline and at the end of the 12-month study period. Records of the echocardiography readings taken before PMVR operation were also obtained.
In group 1, ventricular heart rate was controlled by the β-blocker, digoxin, and a calcium-channel blocker, diltiazem, alone or in combination. The outpatients in group 2 underwent combination pharmacological cardioversion with low-dose oral amiodarone (2 mg/kg), captopril (0.25 mg/kg) and simvastatin (0.3 mg/kg) administered daily and heart rate was maintained at 60 -80 beats/min under quiescent conditions. If necessary, a βblocker (digoxin) and a calcium-channel blocker, diltiazem, alone or in combination, were also administered to these patients. Amiodarone can increase the international normalized ratio (INR), hence INR was monitored and the warfarin dose adjusted accordingly.
During the 12-month follow-up period, the two groups of patients were monitored monthly at the outpatient clinic for heart rate and adverse drug effects, at which time they were also evaluated by physical examination, cardiopulmonary examination, 12-lead ECG analysis, blood tests, and urinalysis. All adverse effects (observed or reported by the patient) were recorded. Adverse electrophysiological effects were considered separately from other adverse effects.
STUDY ENDPOINTS
This study compared combination pharmacological cardioversion therapy with rate control therapy to assess the efficacy and safety of combination therapy with regard to the cumulative number of patients converted to documented sinus rhythm. Pharmacological cardioversion was considered successful when sinus rhythm was maintained for a minimum of 24 h.
STATISTICAL ANALYSIS
All data are presented as mean ± SD for continuous variables and as frequencies for categorical variables. Baseline characteristics were examined for statistical significance using Student's t-test for continuous variables and χ 2 test for categorical variables. Statistical evaluation of the data was carried out using the Statistical Package for Social Sciences (SPSS ® version 13.0; SPSS Inc., Chicago, IL, USA).
We then followed a two-stage approach. Factors associated with cardioversion were first identified at the univariate level. A multivariate stepwise logistic regression model was then used to identify which of the significant univariate parameters contained independent prognostic information for cardioversion. A P-value < 0.05 was considered to be statistically significant.
Results
PATIENT CHARACTERISTICS
From a total of 110 consecutive post-PMVR outpatients with permanent AF, 99 were included in the study. Eight patients were excluded because they did not meet the inclusion/exclusion criteria and three patients refused to participate. Fifty patients YJ Qian, XJ Xiao, HS Yuan et al.
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were randomly selected for rate control therapy (group 1), and 49 for combination pharmacological cardioversion therapy (group 2). One patient in group 2 was excluded at 4 months because of refusal to continue treatment. The baseline demographic and clinical characteristics of each group are shown in Table 1 . The two groups were well matched with regard to all pre-treatment characteristics. Furthermore, no statistical differences were found among the groups in left atrial dimension (LAD) and left ventricular ejection function.
EFFICACY OF ATRIAL FIBRILLATION CONVERSION
During a mean ± SD follow-up period of 12.0 ± 1.3 months, three patients (6%) in the rate control therapy group (group 1) showed conversion to sinus rhythm compared with 19 patients (39%) in the combination therapy group (group 2) (Fig. 1) . The likelihood of conversion significantly differed between the two groups (P < 0.001).
Of the patients in group 2 who successfully converted, 47% did so within 3 months, 84% within 4 months and 95% within 5 months. The analysis showed that the cardioversion rate for combination therapy reached a plateau after 5 months.
As shown in Table 2 , at the univariate level, the change in LAD between preoperative and baseline (∆LAD) was the only clinical parameter that was a significant predictor of successful conversion to sinus rhythm (P = 0.03 by multivariate stepwise logistic regression modelling).
ADVERSE EVENTS DURING FOLLOW-UP
Adverse events requiring discontinuation of treatment occurred in one patient in group 2 because of severe pruritus. Captopril was discontinued in six patients in group 2 after they developed a cough, but the other drugs in the combination therapy continued to be given. None of the patients reported complications related to ventricular arrhythmias during the procedure. No adverse events regarded as treatment related were noted in group 1. All patients were discharged in a stable condition.
Characteristic
Group 1 
Discussion
The present study used low-dose oral amiodarone plus captopril and simvastatin to restore permanent AF to sinus rhythm in post-PMVR outpatients. The combination pharmacological cardioversion therapy was administered on an outpatient basis. As such, it is a novel approach for the treatment The only factor that influenced the effectiveness of combination therapy was ∆LAD; the larger the change, the greater the likelihood of sinus rhythm restoration. However, it has been reported that it is the size of the left atrium or the systolic function of the left ventricle that influences cardioversion effectiveness. 4,17 A variety of cardiac pathologies might explain these discrepancies. The patients in this study concomitantly developed AF and rheumatic valve disease. Structural valve heart disease resulted in conspicuous changes between the pre-operative and baseline LAD, which could have potentially masked the influence exerted by the size of the left atrium.
The Canadian Trial of Atrial Fibrillation (CTAF) and Congestive Heart Failure: Survival Trial of Antiarrhythmic Therapy (CHF STAT) studies have shown that amiodarone is one of the most powerful antiarrhythmic drugs in the prevention of AF recurrence and for gain effect. 18, 19 Unfortunately, currently available drug therapies for AF conversion may have adverse effects or, in extreme cases, increase mortality rates or heart failure. 20 The majority of the side-effects from amiodarone are dose related, especially in patients with organic heart disease. 13, 17 In the CTAF research, where high-dose amiodarone was used, 18% of patients stopped accepting treatment due to adverse reactions in the 16 months of follow-up. 18 In our study, the smaller number of adverse effects and the lower rate of drug discontinuation were probably a result of the relatively low dose of amiodarone administration.
In group 2, the success rate of cardioversion rose during the follow-up period, increased sharply in month 4, and reached 95% within 5 months. This progression may help physicians determine the duration of cardioversion combination therapy. If sinus rhythm cannot be restored within 5 months, treatment should be stopped. However, our results could not provide a time at which treatment should cease in patients who had been successfully cardioverted and needed to maintain sinus rhythm. These conclusions were drawn based on a 12-month follow-up; perhaps prolonging the follow-up period would help optimize long-term maintenance regimens for patients after combination pharmacological cardioversion.
This study had several potential limitations. First, it was a prospective study with subjects being asked to have their cardiac rhythm checked regularly at the outpatient clinic; therefore, the time to cardioversion was not particularly accurate. It is possible that transient or paroxysmal asymptomatic recurrence of AF may have gone undetected. Secondly, the study used a relatively small number of patients with a possibility of bias in patient selection for combination pharmacological cardioversion. Finally, the follow-up period of 12 months was relatively short. Amiodarone, in particular, is known to have side-effects that can take many months to appear. An extended followup period would allow a study of these drug interactions over time and the development of long-term treatment options.
In conclusion, combination pharmacological cardioversion with low-dose oral amiodarone plus captopril and simvastatin is effective in post-PMVR outpatients, and is associated with a relatively low rate of withdrawal and adverse effects. It is a novel approach for the treatment of AF, especially in outpatients who have undergone PMVR or other cardiac surgery.
